The Netherlands Cancer Institute (NKI) and to-BBB to collaborate on brain delivery of anti-cancer drugs

24-Jun-2009 - Netherlands

to-BBB and Dr. Olaf van Tellingen from the Department of clinical chemistry of The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital (NKI-AVL) will collaborate on the development of a potential new therapy for brain tumors.

Chemotherapeutic treatment options for primary and metastatic brain cancer patients are limited and overall prognoses are dismal. To a large extend this is due to the neuroprotective role of the blood-brain barrier (BBB), limiting the safe delivery of many anti-cancer drugs to their disease target in the brain.

The research group of Dr. van Tellingen has developed a series of advanced experimental models to address key topics in the development of new therapies for Brain Tumors, including their transport across the blood-brain barrier.

to-BBB’s G-Technology™ is designed for safe brain delivery of different classes of drugs by formulating these drugs into proprietary glutathione coated stealth liposomes. The G-Technology™ has shown proof of concept in several disease models, based on which the research group of Dr. van Tellingen and to-BBB will join forces to develop brain-targeted liposomes with encapsulated anti-cancer drugs.

https://www.bionity.com/en/news/102394/the-netherlands-cancer-institute-nki-and-to-bbb-to-collaborate-on-brain-delivery-of-anti-cancer-drugs.html